1122 related articles for article (PubMed ID: 19915059)
41. Peripheral 4-1BB signaling negatively regulates NK cell development through IFN-gamma.
Choi BK; Kim YH; Kim CH; Kim MS; Kim KH; Oh HS; Lee MJ; Lee DK; Vinay DS; Kwon BS
J Immunol; 2010 Aug; 185(3):1404-11. PubMed ID: 20610645
[TBL] [Abstract][Full Text] [Related]
42. IL-21: roles in immunopathology and cancer therapy.
Søndergaard H; Skak K
Tissue Antigens; 2009 Dec; 74(6):467-79. PubMed ID: 19845910
[TBL] [Abstract][Full Text] [Related]
43. Characterization of natural killer and natural killer-like T cells derived from ex vivo expanded and activated cord blood mononuclear cells: implications for adoptive cellular immunotherapy.
Ayello J; van de Ven C; Cairo E; Hochberg J; Baxi L; Satwani P; Cairo MS
Exp Hematol; 2009 Oct; 37(10):1216-29. PubMed ID: 19638292
[TBL] [Abstract][Full Text] [Related]
44. A distinct role for ICOS-mediated co-stimulatory signaling in CD4+ and CD8+ T cell subsets.
Watanabe M; Hara Y; Tanabe K; Toma H; Abe R
Int Immunol; 2005 Mar; 17(3):269-78. PubMed ID: 15668466
[TBL] [Abstract][Full Text] [Related]
45. Clonal restriction of the expansion of antigen-specific CD8+ memory T cells by transforming growth factor-{beta}.
Cheng ML; Chen HW; Tsai JP; Lee YP; Shih YC; Chang CM; Ting CC
J Leukoc Biol; 2006 May; 79(5):1033-42. PubMed ID: 16478921
[TBL] [Abstract][Full Text] [Related]
46. Cancer immunotherapy by interleukin-21: potential treatment strategies evaluated in a mathematical model.
Cappuccio A; Elishmereni M; Agur Z
Cancer Res; 2006 Jul; 66(14):7293-300. PubMed ID: 16849579
[TBL] [Abstract][Full Text] [Related]
47. IL-15 is critical for the maintenance and innate functions of self-specific CD8(+) T cells.
Itsumi M; Yoshikai Y; Yamada H
Eur J Immunol; 2009 Jul; 39(7):1784-93. PubMed ID: 19544306
[TBL] [Abstract][Full Text] [Related]
48. Macrophage- and dendritic-cell-derived interleukin-15 receptor alpha supports homeostasis of distinct CD8+ T cell subsets.
Mortier E; Advincula R; Kim L; Chmura S; Barrera J; Reizis B; Malynn BA; Ma A
Immunity; 2009 Nov; 31(5):811-22. PubMed ID: 19913445
[TBL] [Abstract][Full Text] [Related]
49. In vivo antitumor activity of interleukin 21 mediated by natural killer cells.
Wang G; Tschoi M; Spolski R; Lou Y; Ozaki K; Feng C; Kim G; Leonard WJ; Hwu P
Cancer Res; 2003 Dec; 63(24):9016-22. PubMed ID: 14695220
[TBL] [Abstract][Full Text] [Related]
50. Tumor-localized ligation of CD3 and CD28 with systemic regulatory T-cell depletion induces potent innate and adaptive antitumor responses.
Lee CH; Chiang YH; Chang SE; Chong CL; Cheng BM; Roffler SR
Clin Cancer Res; 2009 Apr; 15(8):2756-66. PubMed ID: 19318495
[TBL] [Abstract][Full Text] [Related]
51. Alpha tumor necrosis factor contributes to CD8(+) T cell survival in the transition phase.
Shi M; Ye Z; Umeshappa KS; Moyana T; Xiang J
Biochem Biophys Res Commun; 2007 Aug; 360(3):702-7. PubMed ID: 17618911
[TBL] [Abstract][Full Text] [Related]
52. IL-15R alpha-IgG1-Fc enhances IL-2 and IL-15 anti-tumor action through NK and CD8+ T cells proliferation and activation.
Wu Z; Xu Y
J Mol Cell Biol; 2010 Aug; 2(4):217-22. PubMed ID: 20671116
[TBL] [Abstract][Full Text] [Related]
53. CD4+ T-cell help controls CD8+ T-cell memory via TRAIL-mediated activation-induced cell death.
Janssen EM; Droin NM; Lemmens EE; Pinkoski MJ; Bensinger SJ; Ehst BD; Griffith TS; Green DR; Schoenberger SP
Nature; 2005 Mar; 434(7029):88-93. PubMed ID: 15744305
[TBL] [Abstract][Full Text] [Related]
54. IL-21: a novel IL-2-family lymphokine that modulates B, T, and natural killer cell responses.
Habib T; Nelson A; Kaushansky K
J Allergy Clin Immunol; 2003 Dec; 112(6):1033-45. PubMed ID: 14657853
[TBL] [Abstract][Full Text] [Related]
55. Secretion of interleukin-10 from murine colon carcinoma cells suppresses systemic antitumor immunity and impairs protective immunity induced against the tumors.
Kawamura K; Bahar R; Natsume W; Sakiyama S; Tagawa M
Cancer Gene Ther; 2002 Jan; 9(1):109-15. PubMed ID: 11916240
[TBL] [Abstract][Full Text] [Related]
56. Tumor-derived interleukin-4 reduces tumor clearance and deviates the cytokine and granzyme profile of tumor-induced CD8+ T cells.
Olver S; Groves P; Buttigieg K; Morris ES; Janas ML; Kelso A; Kienzle N
Cancer Res; 2006 Jan; 66(1):571-80. PubMed ID: 16397274
[TBL] [Abstract][Full Text] [Related]
57. Interleukin-21 triggers both cellular and humoral immune responses leading to therapeutic antitumor effects against head and neck squamous cell carcinoma.
Nakano H; Kishida T; Asada H; Shin-Ya M; Shinomiya T; Imanishi J; Shimada T; Nakai S; Takeuchi M; Hisa Y; Mazda O
J Gene Med; 2006 Jan; 8(1):90-9. PubMed ID: 16097036
[TBL] [Abstract][Full Text] [Related]
58. IL-2 responsiveness of CD4 and CD8 lymphocytes: further investigations with human IL-2Rbeta transgenic mice.
Gesbert F; Moreau JL; Thèze J
Int Immunol; 2005 Aug; 17(8):1093-102. PubMed ID: 16037071
[TBL] [Abstract][Full Text] [Related]
59. Blockade of the interleukin-21/interleukin-21 receptor pathway ameliorates disease in animal models of rheumatoid arthritis.
Young DA; Hegen M; Ma HL; Whitters MJ; Albert LM; Lowe L; Senices M; Wu PW; Sibley B; Leathurby Y; Brown TP; Nickerson-Nutter C; Keith JC; Collins M
Arthritis Rheum; 2007 Apr; 56(4):1152-63. PubMed ID: 17393408
[TBL] [Abstract][Full Text] [Related]
60. Type 1 CD8+ T cells are superior to type 2 CD8+ T cells in tumor immunotherapy due to their efficient cytotoxicity, prolonged survival and type 1 immune modulation.
Ye Z; Tang C; Xu S; Zhang B; Zhang X; Moyana T; Yang J; Xiang J
Cell Mol Immunol; 2007 Aug; 4(4):277-85. PubMed ID: 17764618
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
